Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral anti-diabetic drug (OAD). In addition, liraglutide demonstrated the following benefits compared to glimepiride: -Statistically significant reduction in body weight -Statistically significant reduction in risk of hypoglycemia -Statistically significant reduction in systolic blood pressure In this 12-month study, 62% of patients treated with liraglutide who had not been previously treated with diabetes medications achieved an average reduction in blood sugar that brought them below the ADA target for HbA1c of 7%. To view Multimedia News release go to, http://www.prnewswire.com/mnr/novonordisk/33424/